Improving Public Cancer Care by Implementing Precision Medicine in Norway
Status:
Recruiting
Trial end date:
2045-04-30
Target enrollment:
Participant gender:
Summary
IMPRESS-Norway is a prospective, non-randomized clinical trial evaluating efficacy of
commercially available, anti-cancer drugs prescribed for patients with advanced cancer
diagnosed with potentially actionable alterations as revealed by molecular diagnostics.
IMPRESS-Norway is a nation-wide study and all hospitals with an oncology and / or hematology
department will be invited to participate in the study. The study will use a combined
umbrella and basket design and a Simon two-stage model of expanding cohorts to follow up
potentially effective combinations of biomarker and drug on specific indications. Sampling of
biological material will be performed at presentation, during treatment and upon progression.
Additional biomarker and translational analyses including whole genome sequencing (WGS) on
tumour material and liquid biopsies, identifying mechanisms underlying drug sensitivity
versus resistance will be performed.
Phase:
Phase 2
Details
Lead Sponsor:
Oslo University Hospital
Collaborators:
Central Norway Regional Health Authority Haukeland University Hospital Helse Fonna HF Helse Forde Helse Møre og Romsdal HF Helse Nord-Trøndelag HF Helse Stavanger HF Hospital of Southern Norway Trust Nordlandssykehuset HF Ostfold Hospital Trust St. Olavs Hospital Sykehuset Innlandet HF Sykehuset Telemark The Hospital of Vestfold University Hospital of North Norway University Hospital, Akershus Vestre Viken Hospital Trust